Home Office consults on medicinal use of cannabis

Home Office consults on medicinal use of cannabis

June 22 2018 A review into the scheduling of cannabis for medicinal purposes will look for...

Measles outbreaks prompt reminder about MMR vaccination ahead of summer holidays

Measles outbreaks prompt reminder about MMR vaccination ahead of summer holidays

June 22 2018 Young people should ensure they have had both doses of the MMR vaccine, especially...

Smoking levels remain unchanged in Wales at 19%

Smoking levels remain unchanged in Wales at 19%

June 22 2018 A downward trend in the proportion of adults smoking has stalled at 19%, the annual...

GP services get 86% satisfaction rating in Wales

GP services get 86% satisfaction rating in Wales

June 20 2018 The percentage of people reporting they were satisfied with their GP services in...

NICE guideline says people with dementia should be involved in discussions about their care

NICE guideline says people with dementia should be involved in discussions about their care

June 20 2018 An updated NICE guideline has recommended that people with dementia should be...

  • Home Office consults on medicinal use of cannabis

    Home Office consults on medicinal use of cannabis

    Friday, 22 June 2018 16:15
  • Measles outbreaks prompt reminder about MMR vaccination ahead of summer holidays

    Measles outbreaks prompt reminder about MMR vaccination ahead of summer holidays

    Friday, 22 June 2018 15:46
  • Smoking levels remain unchanged in Wales at 19%

    Smoking levels remain unchanged in Wales at 19%

    Friday, 22 June 2018 15:40
  • GP services get 86% satisfaction rating in Wales

    GP services get 86% satisfaction rating in Wales

    Wednesday, 20 June 2018 18:50
  • NICE guideline says people with dementia should be involved in discussions about their care

    NICE guideline says people with dementia should be involved in discussions about their care

    Wednesday, 20 June 2018 18:47

A Resized Recall Image cb1March 6 2018

Zinbryta (daclizumab) is being withdrawn from the market following new concerns about the drug’s side effects. The drug, used by people with multiple sclerosis, is being withdrawn worldwide on a voluntary basis by its manufacturers. 

On Friday, the European Medicines Agency announced that it had started an urgent review of the drug following seven cases of serious inflammatory brain disorders in Germany, including encephalitis and meningoencephalitis, and one case in Spain.

In 2017, following a review of the medicine’s effects on the liver, the EMA had restricted the drug’s use to patients who had tried at least two other disease-modifying treatments and could not be treated with any other MS treatments.

Announcing the review into the effect on brain disorders, the EMA said that “the company that markets Zinbryta (Biogen Idec Ltd) has informed EMA of its intention to voluntarily withdraw the medicine’s marketing authorisations.” Zynbryta is also marketed elsewhere in the world by AbbVie.

Advice issued by the EMA includes:

  • doctors should not start new patients on Zinbryta;
  • doctors should review patients currently treated with Zinbryta and initiate alternative therapy, as soon as possible;
  • patients must not stop their medication without discussing with their doctor;
  • patients who have any questions should talk to their doctor.

The EMA will be contacting EU doctors directly with the information. As Biogen has also informed the EMA of its decision to stop ongoing clinical studies with Zinbryta in the EU, “patients in clinical studies who have any question should contact the doctor treating them in their study.”

Over 8,000 patients worldwide have been treated with Zinbryta. In the EU, the majority of patients are in Germany.

Link:
EMA announcement    

Professional News

June 22 2018 A review into the scheduling of cannabis for medicinal purposes will look for “significant medical and therapeutic benefits” before a decision is made.
June 6 2018 The Royal College of General Practitioners has called for visa regulations to be reviewed to allow more doctors to work as GPs in the NHS. Home Secretary Sajit Javid announced on Sunday...